Name: 글로벌 시장 동향
SKU: PH4034
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 바이오베터 시장 규모는 2022년 453억 3,600만 달러에 달했으며, 2030년까지 859억 1,700만 달러에 이르는 높은 성장세를 보일 것으로 예상됩니다. 전 세계 바이오베터 시장은 예측 기간(2023~2030년) 동안 연평균 8.5%의 성장률을 기록할 것으로 전망됩니다.
바이오베터 시장의 주요 트렌드는 PEGylation 융합 단백질, EKylation, XTEN 기술, Pasylation 등입니다. 융합 단백질은 서로 다른 단백질을 코딩하는 유전자를 결합하여 생성됩니다. 이렇게 생성된 단일 폴리펩티드는 원래 생체 분자 두 가지의 기능적 특성을 모두 나타냅니다.

일반적으로 한 파트너는 분자 인식 기능을 가지고 있고, 다른 파트너는 세포 독성 감소, 반감기 및 안정성 향상, 새로운 표적화 또는 새로운 전달 경로와 같은 특정 기능을 전달합니다. 전 세계 바이오베터 시장은 제품 반감기 연장, 응집 가능성 감소, 효능 향상, 순도 증가, 부작용 감소와 같은 요인에 의해 성장하고 있으며, 바이오시밀러 경쟁 심화는 바이오베터 시장 성장을 제약하는 요인입니다.

시장 동향
바이오베터의 낮은 부작용 이점
바이오베터는 부작용이 적고, 제품 반감기가 길며, 효능이 뛰어난 등 시장 성장을 견인하는 생명공학적 발전입니다.
바이오베터는 개선된 특성으로 인해 프리미엄 가격이 책정될 수 있지만, 투여량 감소로 인해 비용 절감이 가능합니다. 이는 지불자의 제품 구매 의향에 영향을 미칩니다.

PEG화 및 XTEN 기술에 대한 수요 증가
PEG화는 기능성 분자에 폴리에틸렌 글리콜(PEG) 사슬을 공유 결합으로 부착하는 기술로, 약물 동태를 개선하고 독성 및 면역원성을 감소시키는 데 효과적입니다. 생물학적 제제의 한계를 극복하는 주요 접근 방식으로 자리 잡았으며, 시중에는 PEG화 제품의 수가 증가하고 있습니다. PEG화 단백질은 크기와 유체역학적 부피 증가, 면역원성 감소, 생체 내 단백질 분해 및 세포내이입에 대한 보호, 수용성 증가, 입체적 반발로 인한 단백질 응집 감소, 열적 및 기계적 안정성 증가 등의 특징을 나타냅니다.
XTEN 기술(XTENylation이라고도 함)은 알라닌, 글루탐산, 글리신, 프롤린, 세린, 트레오닌 잔기로만 구성된 864개의 아미노산으로 이루어진 비구조적 재조합 폴리펩티드를 유전적으로 융합하는 기술입니다. 이 기술은 단백질의 혈청 반감기, 수용성 및 안정성을 향상시켜 용액 상태에서의 발현 및 제조를 가능하게 하는 것으로 입증되었습니다.

바이오시밀러 경쟁 심화
바이오베터 시장에서 바이오시밀러 경쟁이 심화되면서 예측 기간 동안 시장 성장이 저해될 것으로 예상됩니다. 바이오시밀러 개발의 진전은 바이오베터 시장 수요를 감소시키고 있습니다.
코로나19 영향 분석
류마티스 관절염이나 염증성 장 질환과 같은 자가면역 질환 환자는 코로나19 감염 위험이 높습니다. 이에 영국에서는 정맥 주사 치료를 받는 환자들이 피하 주사로 전환할 수 있는지 평가하도록 하는 새로운 지침이 발표되었습니다.
병원 기반 정맥 주입 치료에서 피하 주사 투여로의 전환은 차세대 혁신 치료제인 바이오베터가 환자들이 필요한 치료를 적시에 받을 수 있도록 돕는 중요한 도구가 될 수 있음을 보여주는 사례입니다. 코로나19 팬데믹 기간 동안 바이오베터 개발이 진전되었으며, 몇 가지 주목할 만한 변화도 관찰되었습니다.

러시아-우크라이나 분쟁 분석
전 세계 과학계에 미치는 전쟁의 장기적인 영향과 러시아-우크라이나 전쟁 기간 동안 우크라이나의 학계, 의학계, 과학 분야에서 연구 기회를 놓친 것에 대한 위험성을 분석합니다.
미국 식품의약국(FDA)의 임상시험 데이터베이스에 따르면, 우크라이나는 251개의 의약품, 의료기기, 약물을 시험하고 있었습니다. 또한, 2022년에는 우크라이나에서 1,000건 이상의 의약품 임상시험이 진행 중이거나 계획되어 있었습니다. 러시아-우크라이나 전쟁은 바이오베터 시장에 영향을 미쳐 의약품, 약물, 의료기기에 대한 수요는 증가했지만, 일부 지역에서는 바이오베터 시장 수요가 감소하는 결과를 초래했습니다.

시장 세분화 분석
글로벌 바이오베터 시장은 약물 종류, 적용 분야, 투여 경로 및 유통 채널별로 세분화됩니다.
이중특이항체 바이오베터 부문이 바이오베터 시장을 주도할 것으로 예상됩니다.
이중특이항체 바이오베터 부문은 약 36.1%의 시장 점유율을 차지하며 바이오베터 시장을 주도할 것으로 예상됩니다. 선진 의료 인프라와 기술의 빠른 발전은 예측 기간 동안 바이오베터 시장 성장을 촉진하는 데 중요한 역할을 할 것으로 전망됩니다.
이중특이항체(BsAbs)는 두 개의 항원 또는 동일한 항원의 두 에피토프를 표적으로 하는 두 개의 결합 부위로 구성됩니다. 이중특이항체의 주요 응용 분야는 항체 의존성 세포 매개성 세포독성(ADCC) 및 기타 면역 효과 세포가 수행하는 세포독성 메커니즘을 통해 종양 세포 사멸을 향상시키도록 면역 효과 세포를 전환하는 것입니다.

지리적 분석
북미 지역은 전 세계 바이오베터 시장에서 약 39.4%의 가장 큰 시장 점유율을 차지하고 있습니다.
바이오베터는 생물학적 제제 승인 경로를 통해 승인되며, 북미 지역에서 10~12년의 시장 독점권을 부여받습니다. 미국은 전 세계 바이오의약품 시장의 3분의 1을 차지하는 세계 선두 주자입니다. 전 세계 신약 연구 개발 및 지적 재산권의 절반 이상을 미국이 보유하고 있습니다.
경쟁 환경
주요 글로벌 기업으로는 Amgen Inc., Merck KGaA., Mabpharm Limited, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Celltrion Healthcare, Novo Nordisk A/S, Biogen, Aequilibrium Pharma, Pfizer 등이 있습니다.
보고서 구매 이유

• 제품, 적용 분야 및 지역별 글로벌 바이오베터 시장 세분화를 시각화하고 주요 상업 자산 및 주요 기업을 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 글로벌 바이오베터 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 기업의 핵심 제품을 모두 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 바이오베터 시장 보고서는 약 54개의 표, 46개의 그림, 195페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The global biobetters market size reached US$ 45,336.0 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 85,917.0 million by 2030. The global biobetters market is exhibiting at a CAGR of 8.5% during the forecast period (2023-2030).
The market trends of biobetters are PEGylation fusion proteins, EKylation, XTEN technology, Pasylation, and so on. Fusion proteins are created by combining genes that encode separate proteins. The single polypeptide produced displays the functional properties of both originator biomolecules.
Commonly, one partner has a molecular recognition function while the other transfers a certain functionality, such as decreased cytotoxicity, improved half-life, and stability, novel targeting, or a new delivery route.The global biobetters market is driven by factors such as longer product half-life, lower likelihood of aggregation, greater efficacy, purity, and fewer adverse events and the increasing biosimilar competition restraints the biobetters market growth.
Market Dynamics
The Advantage of Lower Adverse Effect of Biobetters
Biobetters are biotechnological advancements that have lower adverse effects, longer product
half-life, greater efficacy, and other driving factors, driving the market growth.
A biobetter can be assigned a premium price due to its improved characteristics, but cost savings
can be achieved due to reduced dosages. This affects payers' willingness to purchase the product.
Growing Demand for PEGylation, and XTEN Technology
PEGylation is the covalent attachment of polyethylene glycol (PEG) chains to a functional molecule, which is effective in improving pharmacokinetics and reducing toxicity and immunogenicity. It has become the main approach to overcome the limitations of biological drugs, with an increasing number of PEGylated products on the market. PEGylated proteins are characterized by increased size and hydrodynamic volume, reduced immunogenicity, protection against in vivo proteolysis and endocytosis, greater solubility in water, decreased protein aggregation due to steric repulsion, and increased thermal and mechanical stability.
XTEN technology also known as XTENylation is a genetic fusion of an unstructured recombinant polypeptide of 864 amino acids, composed entirely of alanine, glutamate, glycine, proline, serine, and threonine residues. It has been demonstrated to increase the serum half-life and water solubility and stability of proteins, allowing their expression in solution and manufacturing.
Increasing Biosimilar Competition
Increasing biosimilar competition for the biobetters restraining the market growth during the forecast period. Advancements in the development of biosimilars is decreasing the demand for biobetter market.
COVID-19 Impact Analysis
Autoimmune conditions such as rheumatoid arthritis or inflammatory bowel disease are at higher risk of Covid-19 infection, and then new guidance was issued in the UK to ensure that patients receiving intravenous treatment were assessed for possible switching to the same therapy in subcutaneous form.
This switch from hospital-based intravenous infusion therapy to administration via subcutaneous injection is an example of how biobetters, a new generation of innovative therapeutic medicines, could become an important tool to help ensure that patients can gain access to the treatment they need in a timely fashion. During the COVID-19 pandemic, advancements in the biobetters are seen, and some anticipating conditions have also been noticed.
Russia-Ukraine Conflict Analysis
Risk about the war's long-term impact on the scientific community worldwide and the missed opportunities for research in Ukraine's academic, medical, and scientific disciplines during Russia Ukraine war.
Ukraine was testing 251 medicines, devices, and drugs, according to the FDA's clinical trials database. According to the clinical trials database, in 2022, over 1,000 medication clinical trials were underway or planned in Ukraine. The Russia-Ukraine war impacted the biobetters market, resulting in increased demand for medicines, drugs, and medical devices, and in some cases decreased demand for the biobetters market in the region.
Segment Analysis
The global biobetters market is segmented based on Drug Class, By Application, By Route of Administration and By Distribution Channel
Bispecific Antibodies Biobetters Segment is Expected to Dominate the Biobetters Market
The bispecific antibodies biobetters segment is expected to dominate the biobetters capturing a market share of around 36.1%. The advanced healthcare infrastructure coupled with rapid advancements in technology is expected to play an imperative role in boosting the growth of the biobetters market in the forecast period.
Bispecific antibodies (BsAbs) consist of two binding sites directed at two antigens or two epitopes of the same antigen. The primary application of BsAbs has been to shift cytotoxic immune effector cells for the enhanced killing of tumor cells by Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and other cytotoxic mechanisms carried out by the effector cells.
Geographical Analysis
North America Region Holds the Largest Market Share of Around 39.4% in the Global Biobetters Market
Biobetters are approved through the biologics approval pathway, providing 10-12 years of market exclusivity in the North American region. The United States is the global leader in the Biopharmaceutical market, accounting for one-third of the global market. Over half of the world's R&D and Intellectual Property Rights of most new medicines are held by the United States.
Competitive Landscape
The major global players include Amgen Inc., Merck KGaA., Mabpharm Limited, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Celltrion Healthcare, Novo Nordisk A/S, Biogen, Aequilibrium Pharma, Pfizer, and others.
Why Purchase the Report?
• To visualize the global biobetters market segmentation based on product, application, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global biobetters market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global biobetters market report would provide approximately 54 tables, 46 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Application
3.3. Snippet by Route of Administration
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Lower adverse effects
4.1.1.2. Longer Product Half-life
4.1.2. Restraints
4.1.2.1. Increasing Biosimilar Competition
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Bispecific Antibodies Biobetters
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. PEGylation Biobetters
7.4. Glyco-engineering Biobetters
7.5. Fc Engineering Biobetters
7.6. Antibody Fragment Biobetters
7.7. Antibody Drug Conjugation (ADC) Biobetters
7.8. Fusion Protein Biobetters
7.9. Bio Prodrug/Bioprecursor Biobetters
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Cancer*
8.2.1. Introduction
8.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Diabetes
8.4. Renal Disease
8.5. Neurodegenerative Disease
8.6. Genetic Disorders
8. By Route of Administration
8.5. Introduction
8.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.5.2. Market Attractiveness Index, By Route of Administration
8.6. Subcutaneous
8.6.1. Introduction
8.6.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.7. Intravenous
8.8. Oral
8.9. Inhaled
8.10. Intramuscular
9. By Region
9.5. Introduction
9.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.5.2. Market Attractiveness Index, By Region
9.6. North America
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.6.7.1. Canada
9.6.7.2. Mexico
9.7. Europe
9.7.1. Introduction
9.7.2. Key Region-Specific Dynamics
9.7.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.7.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.7.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.7.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.7.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.7.7.1. Germany
9.7.7.2. The U.K.
9.7.7.3. France
9.7.7.4. Italy
9.7.7.5. Spain
9.7.7.6. Rest of Europe
9.8. South America
9.8.1. Introduction
9.8.2. Key Region-Specific Dynamics
9.8.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.8.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.8.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.8.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.8.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.8.7.1. Brazil
9.8.7.2. Argentina
9.8.7.3. Rest of South America
9.9. Asia-Pacific
9.9.1. Introduction
9.9.2. Key Region-Specific Dynamics
9.9.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.9.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.9.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.9.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.9.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.9.7.1. China
9.9.7.2. India
9.9.7.3. Japan
9.9.7.4. Australia
9.9.7.5. Rest of Asia-Pacific
9.10. Middle East and Africa
9.10.1. Introduction
9.10.2. Key Region-Specific Dynamics
9.10.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.10.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10. Competitive Landscape
10.5. Competitive Scenario
10.6. Market Positioning/Share Analysis
10.7. Mergers and Acquisitions Analysis
11. Company Profiles
11.5. Amgen Inc*
11.5.1. Company Overview
11.5.2. Product Portfolio and Description
11.5.3. Financial Overview
11.5.4. Key Developments
11.6. Merck KGaA.
11.7. Mabpharm Limited
11.8. F. Hoffmann-La Roche Ltd
11.9. GlaxoSmithKline plc
11.10. CELLTRION INC.
11.11. Novo Nordisk A/S
11.12. Biogen
11.13. Aequilibrium Pharma
11.14. Pfizer Inc
LIST NOT EXHAUSTIVE
12. Appendix
12.5. About Us and Services
12.6. Contact Us

언급된 주요 기업들

Amgen Inc, 4.	Key Developments, Merck KGaA., Mabpharm Limited, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, CELLTRION INC., Novo Nordisk A/S, Biogen, Aequilibrium Pharma, Pfizer Inc

표 목록 (Tables)

List of Tables Table 1 Global Biobetters Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)

Table 2 Global Biobetters Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)

Table 3 Global Biobetters Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)

Table 4 Global Biobetters Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 5 Global Biobetters Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)

Table 6 Global Biobetters Market Value, By Type, 2022-2033 (US$ Billion)

Table 7 Global Biobetters Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)

Table 8 Global Biobetters Market Value, By Application, 2022-2033 (US$ Billion)

Table 9 Global Biobetters Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)

Table 10 Global Biobetters Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 11 Global Biobetters Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 12 Global Biobetters Market Value, By Region, 2022-2033 (US$ Billion)

Table 13 North America Biobetters Market Value, By Type, 2022-2033 (US$ Billion)

Table 14 North America Biobetters Market Value, By Application, 2022-2033 (US$ Billion)

Table 15 North America Biobetters Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 16 North America Biobetters Market Value, By Country, 2022-2033 (US$ Billion)

Table 17 Europe Biobetters Market Value, By Type, 2022-2033 (US$ Billion)

Table 18 Europe Biobetters Market Value, By Application, 2022-2033 (US$ Billion)

Table 19 Europe Biobetters Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 20 Europe Biobetters Market Value, By Country, 2022-2033 (US$ Billion)

Table 21 Asia-Pacific Biobetters Market Value, By Type, 2022-2033 (US$ Billion)

Table 22 Asia-Pacific Biobetters Market Value, By Application, 2022-2033 (US$ Billion)

Table 23 Asia-Pacific Biobetters Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 24 Asia-Pacific Biobetters Market Value, By Country, 2022-2033 (US$ Billion)

Table 25 South America Biobetters Market Value, By Type, 2022-2033 (US$ Billion)

Table 26 South America Biobetters Market Value, By Application, 2022-2033 (US$ Billion)

Table 27 South America Biobetters Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 28 South America Biobetters Market Value, By Country, 2022-2033 (US$ Billion)

Table 29 Middle East and Africa Biobetters Market Value, By Type, 2022-2033 (US$ Billion)

Table 30 Middle East and Africa Biobetters Market Value, By Application, 2022-2033 (US$ Billion)

Table 31 Middle East and Africa Biobetters Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 32 Middle East and Africa Biobetters Market Value, By Country, 2022-2033 (US$ Billion)

Table 33 Celltrion, Inc.: Overview

Table 34 Celltrion, Inc.: Product Portfolio

Table 35 Celltrion, Inc.: Key Developments

Table 36 Altos Biologics Co., Ltd.: Overview

Table 37 Altos Biologics Co., Ltd.: Product Portfolio

Table 38 Altos Biologics Co., Ltd.: Key Developments

Table 39 Amgen Inc.: Overview

Table 40 Amgen Inc.: Product Portfolio

Table 41 Amgen Inc.: Key Developments

Table 42 Novo Nordisk A/S: Overview

Table 43 Novo Nordisk A/S: Product Portfolio

Table 44 Novo Nordisk A/S: Key Developments

Table 45 Eli Lilly and Company: Overview

Table 46 Eli Lilly and Company: Product Portfolio

Table 47 Eli Lilly and Company: Key Developments

Table 48 Sanofi SA: Overview

Table 49 Sanofi SA: Product Portfolio

Table 50 Sanofi SA: Key Developments

Table 51 Genentech USA, Inc.: Overview

Table 52 Genentech USA, Inc.: Product Portfolio

Table 53 Genentech USA, Inc.: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 2 Global Biobetters Market Share, By Type, 2024 & 2033 (%)

Figure 3 Global Biobetters Market Share, By Application, 2024 & 2033 (%)

Figure 4 Global Biobetters Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 5 Global Biobetters Market Share, By Region, 2024 & 2033 (%)

Figure 6 Global Biobetters Market Y-o-Y Growth, By Type, 2023-2033 (%)

Figure 7 Platelet-Rich Plasma (PRP) Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 8 Bone Morphogenetic Proteins (BMP) Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 9 Bone Marrow Aspirate (BMA) Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 10 Bone Marrow Aspirate Concentrate (BMAC) Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 11 Bone Grafts Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 12 Demineralized Bone Matrix (DBM) Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 13 Stem Cells Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 14 Others Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 15 Global Biobetters Market Y-o-Y Growth, By Application, 2023-2033 (%)

Figure 16 Osteoarthritis & Degenerative Arthritis Application in Global Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 17 Spinal Fusion Application in Global Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 18 Fracture Recovery Application in Global Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 19 Soft Tissue Injuries Application in Global Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 20 Maxillofacial & Dental Applications Application in Global Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 21 Others Application in Global Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 22 Global Biobetters Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)

Figure 23 Hospitals Distribution Channel in Global Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 24 Orthopedic Clinics Distribution Channel in Global Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 25 Academic and Research Institutes Distribution Channel in Global Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 26 Others Distribution Channel in Global Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 27 Global Biobetters Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 28 North America Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 29 North America Biobetters Market Share, By Type, 2024 & 2033 (%)

Figure 30 North America Biobetters Market Share, By Application, 2024 & 2033 (%)

Figure 31 North America Biobetters Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 32 North America Biobetters Market Share, By Country, 2024 & 2033 (%)

Figure 33 Europe Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 34 Europe Biobetters Market Share, By Type, 2024 & 2033 (%)

Figure 35 Europe Biobetters Market Share, By Application, 2024 & 2033 (%)

Figure 36 Europe Biobetters Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 37 Europe Biobetters Market Share, By Country, 2024 & 2033 (%)

Figure 38 Asia-Pacific Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 39 Asia-Pacific Biobetters Market Share, By Type, 2024 & 2033 (%)

Figure 40 Asia-Pacific Biobetters Market Share, By Application, 2024 & 2033 (%)

Figure 41 Asia-Pacific Biobetters Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 42 Asia-Pacific Biobetters Market Share, By Country, 2024 & 2033 (%)

Figure 43 South America Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 44 South America Biobetters Market Share, By Type, 2024 & 2033 (%)

Figure 45 South America Biobetters Market Share, By Application, 2024 & 2033 (%)

Figure 46 South America Biobetters Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 47 South America Biobetters Market Share, By Country, 2024 & 2033 (%)

Figure 48 Middle East and Africa Biobetters Market Value, 2022-2033 (US$ Billion)

Figure 49 Middle East and Africa Biobetters Market Share, By Type, 2024 & 2033 (%)

Figure 50 Middle East and Africa Biobetters Market Share, By Application, 2024 & 2033 (%)

Figure 51 Middle East and Africa Biobetters Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 52 Celltrion, Inc.: Financials

Figure 53 Altos Biologics Co., Ltd.: Financials

Figure 54 Amgen Inc.: Financials

Figure 55 Novo Nordisk A/S: Financials

Figure 56 Eli Lilly and Company: Financials

Figure 57 Sanofi SA: Financials

Figure 58 Genentech USA, Inc.: Financials

글로벌 바이오베터 시장 – 2023-2030

Global Biobetters Market - 2023-2030